Analyzing Control-IQ Technology Data
With t:connect Web Application Reports

Our t:connect web application and reports have been updated with Control-IQ technology. Take a moment to see what’s new.

Dashboard
The Dashboard on the t:connect® web application provides a general overview of overall glycemic control including percentage of time above, within, and below the target range. It also summarizes average daily insulin use and data from Control-IQ® technology.

A The average continuous glucose monitoring (CGM) value when Control-IQ technology is in use. This may differ from the average CGM reading on the dashboard.
B The amount of time Control-IQ technology was in closed-loop.
C The amount of time the patient turned off Control-IQ technology.
D The amount of time CGM is inactive due to loss of signal, sensor errors or the sensor session is inactive.
E The amount of time the t:slim X2™ insulin pump is inactive due to a cartridge change, manual suspension, or alarm suspension.
F The average duration the Sleep Activity setting was in use.
G The number of times that the Exercise Activity was started.

Logbook
The Logbook displays the total basal delivered within each hour (H) and the programmed Basal Profile Setting (I). With Control-IQ technology these basal rates may differ.
Printed Therapy Timeline
The printed Therapy Timeline displays seven days of data across two pages including glucose readings, basal rates, and Control-IQ events (e.g., Activity settings and correction boluses). A therapy summary box will also show pertinent CGM, insulin, and carbohydrate data.

A Automatic Correction Bolus
B Exercise Activity
C Sleep Activity
D Override Bolus
E Programmed Basal Rate
F Control-IQ Basal Rate
G Control-IQ Suspensions
**Stepwise Approach to Analyzing Control-IQ Technology**

The following section addresses two topics: the suggested order for reviewing reports and some items to look for within each reporting segment. Before printing reports, verify glycemic thresholds are set appropriately in the t:connect web application.

### 1. Dashboard: Overview

| CGM Summary | Goal is <25% for Above Target Range (>180 mg/dL)³
|             | Goal is >70% for Target Range (70-180 mg/dL)³
|             | Goal is <4% for Below Target Range (<70 mg/dL)³
| Control-IQ Technology | If Time in Use is <90%, assess reason for pump or CGM inactivity
|                   | Check if Sleep Activity is programmed and being used
|                   | Check if Exercise Activity is being used for physical activity
| Average Daily Insulin Summary | Assess ratio of basal to bolus delivery
|                   | Update total daily insulin as needed
| Change Frequency | Check if infusion set is changed every two to three days

### 2. CGM Hourly Report: Glycemic Patterns

| Box-and-Whisker CGM Graph | Shorter boxes = Less glycemic variability
|                          | Taller boxes = Greater glycemic variability
| Time of Day Boxes | Assess and identify glycemic trends throughout the morning, afternoon, evening, and overnight

### 3. Therapy Timeline: Glycemic Trends

| CGM Tracing | Assess CGM tracing and identify if there are patterns (e.g., overnight, hypoglycemia, pre-prandial, and post-prandial)
| Bolus Delivery | Assess cause and effect relationships of bolus deliveries and Control-IQ events (i.e., Sleep and Exercise Activities)
| Basal Rates | Assess differences between profile and Control-IQ basal rates
| Diabetes Self-Management Education | Determine if the patient needs additional self-management education (see Control-IQ technology therapy tips on back page) and/or their pump settings need adjustment (see step 4)

*continued on next page*
**Analyzing Control-IQ Technology Data**

### Stepwise Approach to Analyzing Control-IQ Technology (continued)

#### Device Settings

<table>
<thead>
<tr>
<th>Personal Profile Settings</th>
<th>Review pump settings. If necessary, the following personal profile settings can be modified:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Basal rate</td>
<td></td>
</tr>
<tr>
<td>• Correction factor</td>
<td></td>
</tr>
<tr>
<td>• Insulin to carbohydrate ratio</td>
<td></td>
</tr>
</tbody>
</table>

*Note: target blood glucose (110 mg/dL) and active insulin duration (5 hours) cannot be modified when using Control-IQ technology.*

---

**Control-IQ Technology Therapy Tips**

- Use caution when overriding boluses. Extra insulin may already be on board from increased basal rates and automatic correction boluses.
- Consider programming a separate Personal Profile (e.g., weekday, weekend, exercise, hormones).
- Continue to give manual correction boluses as needed.
- Pre-meal boluses are still required.
- Consider treating hypoglycemia with 5-10 grams of carbohydrate, especially if basal delivery has been stopped.
- Utilize the Exercise Activity to set a higher range of treatment values.
- Utilize the Sleep Activity and program Sleep Schedules for at least five hours.

---

**Important Safety Information:**

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and Control-IQ technology to sale by or on the order of a physician. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are intended for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (CGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on CGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater.

**WARNING:** Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

© 2020 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care and t:connect are registered trademarks and Control-IQ and t:slim X2 are trademarks of Tandem Diabetes Care, Inc. All other third-party marks are the property of their respective owners. ML-1006081_A